Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Nivolumab-Ipilimumab

Details

Generic Name:
Nivolumab-Ipilimumab
Project Status:
Complete
Therapeutic Area:
NSCLC
Manufacturer:
Bristol-Meyers Squibb Canada
Brand Name:
Opdivo-Yervoy
Project Line:
Reimbursement Review
Project Number:
PC0218-000
Tumour Type:
Lung
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Nivolumab (Opdivo), in combination with ipilimumab (Yervoy) and 2 cycles of platinum-based chemotherapy​
Recommendation Type:
Reimburse with clinical criteria and/or conditions
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 29, 2025